CYTK Cytokinetics Inc

Price (delayed)

$36.3

Market cap

$3.03B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.2

Enterprise value

$3.23B

Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by ...

Highlights
CYTK's equity has surged by 121% year-on-year but it has dropped by 76% since the previous quarter
The EPS has contracted by 9% from the previous quarter but it has grown by 6% YoY
The debt has soared by 73% YoY and by 7% from the previous quarter
Cytokinetics's quick ratio has plunged by 52% from the previous quarter and by 40% YoY

Key stats

What are the main financial stats of CYTK
Market
Shares outstanding
83.51M
Market cap
$3.03B
Enterprise value
$3.23B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
157.93
Price to sales (P/S)
45.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
55.93
Earnings
Revenue
$57.8M
EBIT
-$139.71M
EBITDA
-$137.62M
Free cash flow
-$17.06M
Per share
EPS
-$2.2
Free cash flow per share
-$0.24
Book value per share
$0.23
Revenue per share
$0.81
TBVPS
$7.86
Balance sheet
Total assets
$564.3M
Total liabilities
$547.81M
Debt
$238.51M
Equity
$16.49M
Working capital
$302.46M
Liquidity
Debt to equity
14.46
Current ratio
5.9
Quick ratio
5.72
Net debt/EBITDA
-1.46
Margins
EBITDA margin
-238.1%
Gross margin
100%
Net margin
-269.5%
Operating margin
-219.1%
Efficiency
Return on assets
-29%
Return on equity
-179.4%
Return on invested capital
-23.6%
Return on capital employed
-27.8%
Return on sales
-241.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CYTK stock price

How has the Cytokinetics stock price performed over time
Intraday
-1.97%
1 week
1.48%
1 month
9.57%
1 year
121.48%
YTD
74.69%
QTD
1.57%

Financial performance

How have Cytokinetics's revenue and profit performed over time
Revenue
$57.8M
Gross profit
$57.8M
Operating income
-$126.63M
Net income
-$155.76M
Gross margin
100%
Net margin
-269.5%
The net margin has soared by 64% YoY but it has decreased by 17% from the previous quarter
Cytokinetics's operating margin has soared by 63% YoY but it has decreased by 23% from the previous quarter
Cytokinetics's operating income has decreased by 22% from the previous quarter and by 15% YoY
The net income is down by 15% since the previous quarter and by 11% year-on-year

Growth

What is Cytokinetics's growth rate over time

Valuation

What is Cytokinetics stock price valuation
P/E
N/A
P/B
157.93
P/S
45.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
55.93
The EPS has contracted by 9% from the previous quarter but it has grown by 6% YoY
CYTK's equity has surged by 121% year-on-year but it has dropped by 76% since the previous quarter
CYTK's P/S is 96% above its 5-year quarterly average of 23.0 and 73% above its last 4 quarters average of 26.0

Efficiency

How efficient is Cytokinetics business performance
The ROS has soared by 65% YoY but it has contracted by 19% from the previous quarter
The company's return on assets has surged by 50% YoY and by 2.4% QoQ
CYTK's return on invested capital is up by 47% year-on-year and by 3.7% since the previous quarter
The return on equity is up by 16% since the previous quarter

Dividends

What is CYTK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CYTK.

Financial health

How did Cytokinetics financials performed over time
The total assets is 3% greater than the total liabilities
The total assets has surged by 143% year-on-year but it has declined by 2.2% since the previous quarter
Cytokinetics's total liabilities has soared by 76% YoY and by 8% from the previous quarter
CYTK's equity has surged by 121% year-on-year but it has dropped by 76% since the previous quarter
The debt has soared by 73% YoY and by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.